Biorchestra Co., Ltd.

Jin-Hyeob Ryu

Hyun-Jeong Cho

Hyun Su Min

Dae Hoon Kim

Han Seok Koh

Yu Na Lim

The present disclosure relates to a method for diagnosing or providing information for diagnosing Alzheimer's disease or a brain disease, and a composition and a diagnostic kit for diagnosing Alzheimer's disease or a brain disease using miR-485-3p. The present disclosure enables objective data analysis of the diagnosis of Alzheimer's disease or a brain disease by measuring the expression level of miR-485-3p in blood, minimizes risk to a patient by measuring the concentration of amyloid beta 42 in saliva, and enables quick and accurate diagnosis. Accordingly, the present disclosure is very useful for preventing Alzheimer's disease or a brain disease.

Method for diagnosis of Alzheimer's disease using microrna

The present disclosure includes cationic carrier units comprising (i) a water soluble polymer, (ii) a positively charged carrier, and (iii) an adjuvant moiety, wherein when the cationic carrier unit is mixed with an anionic payload (e.g., an antisense oligonucleotide) that electrostatically interacts with the cationic carrier unit, the resulting composition self-organizes into a micelle encapsulating the anionic payload in its core. The cationic carrier units can also comprise a tissue specific targeting moiety, which would be displayed on the surface of the micelle. The disclosure also includes micelles comprising the cationic carrier units of the disclosure, methods of manufacture of cationic carrier units and micelles, pharmaceutical compositions comprising the micelles, and also methods of treating diseases or conditions comprising administering the micelles to a subject in need thereof.

Micellar nanoparticles and uses thereof

The present disclosure relates to a pharmaceutical composition for preventing or treating a brain disease, more particularly to a pharmaceutical composition for preventing or treating a brain disease, which contains a miR-485-3p inhibitor, and a method for screening an agent for preventing or treating a brain disease, which includes a step of measuring the expression level of miR-485-3p. Because the composition for treating a brain disease, which contains a miR-485-3p inhibitor, can restore the ELAVL2 protein unlike the exiting therapeutic agents for Alzheimer's disease, which are limited only to alleviating symptoms by inducing decreased expression of amyloid beta 42, the present disclosure can fundamentally treat various diseases caused by decreased expression of ELAVL2, such as Alzheimer's disease, autism spectrum disorder, mental retardation, amyotrophic lateral sclerosis, etc. Therefore, the present disclosure is useful for treating brain diseases including Alzheimer's disease fundamentally.

Uses for prevention or treatment of brain diseases using microRNA

Method for diagnosis of Alzheimer's disease using microRNA

Uses for prevention or treatment of brain diseases using microrna

Growing community of inventors

Daejeon, South Korea

Jin-Hyeob Ryu